Savant Capital LLC cut its holdings in shares of Embecta Corp. (NASDAQ:EMBC – Free Report) by 29.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,579 shares of the company’s stock after selling 6,483 shares during the period. Savant Capital LLC’s holdings in Embecta were worth $322,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of EMBC. Quarry LP acquired a new stake in shares of Embecta during the third quarter valued at about $30,000. Copeland Capital Management LLC acquired a new position in Embecta in the third quarter worth about $43,000. CWM LLC grew its stake in Embecta by 11.3% in the third quarter. CWM LLC now owns 10,102 shares of the company’s stock worth $142,000 after purchasing an additional 1,023 shares in the last quarter. SG Americas Securities LLC acquired a new position in Embecta in the third quarter worth about $207,000. Finally, Intech Investment Management LLC acquired a new position in Embecta in the third quarter worth about $211,000. 93.83% of the stock is currently owned by institutional investors and hedge funds.
Embecta Stock Down 8.0 %
Shares of EMBC stock opened at $14.85 on Tuesday. The business has a 50 day moving average of $19.12 and a two-hundred day moving average of $16.57. Embecta Corp. has a 52 week low of $9.93 and a 52 week high of $21.48. The company has a market cap of $863.29 million, a P/E ratio of 14.85, a PEG ratio of 0.95 and a beta of 1.20.
Embecta Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, March 14th. Shareholders of record on Friday, February 28th will be issued a $0.15 dividend. The ex-dividend date is Friday, February 28th. This represents a $0.60 annualized dividend and a dividend yield of 4.04%. Embecta’s dividend payout ratio is currently 60.00%.
Insider Buying and Selling at Embecta
In other Embecta news, Director Milton Mayo Morris sold 3,100 shares of Embecta stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $16.38, for a total transaction of $50,778.00. Following the transaction, the director now directly owns 36,133 shares in the company, valued at approximately $591,858.54. The trade was a 7.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.42% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of research firms recently commented on EMBC. BTIG Research upgraded Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price target for the company in a research note on Wednesday, November 27th. Morgan Stanley upgraded Embecta from an “underweight” rating to an “equal weight” rating and lifted their price target for the stock from $13.00 to $20.00 in a research note on Monday, December 2nd.
Check Out Our Latest Research Report on Embecta
Embecta Company Profile
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Recommended Stories
- Five stocks we like better than Embecta
- What is an Earnings Surprise?
- Airbnb’s Earnings: Sky High Results, Grounded Guidance?
- Using the MarketBeat Dividend Yield Calculator
- Kyndryl Soars on AI, Cybersecurity Growth—What’s Next?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Conflicting Signals: Tempus AI’s Stock Market Rally
Want to see what other hedge funds are holding EMBC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Embecta Corp. (NASDAQ:EMBC – Free Report).
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.